Aims of these analyses were to ( 1 ) develop a population pharmacokinetic-pharmacodynamic model for describing the relationship between axitinib exposure and changes in diastolic BP ( dBP ) and ( 2 ) simulate changes in dBP with different axitinib dosing regimens .